National Cancer Institute (NCI)
Bethesda, Maryland, 20892, United States
NCT Number: NCT00026936
The utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a clinical setting will be assessed by comparing results with other fully three-dimensional programs. ROB will investigate PEREGRINE for clinical use at NCI in collaboration with Lawrence Livermore National Laboratory (LLNL).
Looking for future studies?
Notify MeThe utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a clinical setting will be assessed by comparing results with other fully three-dimensional programs. ROB will investigate PEREGRINE for clinical use at NCI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with documented malignancy requiring standard radiotherapy OR patients with a benign condition for whom radiotherapy is indicated.
Exclusion criteria
Documented connective tissue disease or Ataxia Telangiectasia.
Cognitively impaired patients who cannot give informed consent.
Other medical conditions deemed by the PI to make the patient ineligible.
Patients requiring emergent radiotherapy.
Patients who are not able to undergo a CT scan.
National Cancer Institute (NCI)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07192926
Atrophy, Bronchial Neoplasms
Ankara, Yenimahalle, Turkey (Türkiye)
View Trial DetailsNCT02851706
Astrocytoma, Brain Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT05909202
Caregivers, Neoplasm
Bethesda, Maryland, United States
View Trial DetailsNCT04142567
Neoplasm, Neoplasms
Paris, France
View Trial Details